🔥Telegram İfşa

We should be screening everyone with hypertension for primary aldosteronism, according to the recently released Endocrine Society guidelines. Follow this diagnostic algorithm Full guidelines: academic.oup.com/jcem/article/1…

Looking forward to Kevin Hall’s new book. Glad to see there’s an audiobook too for us auditory learners

“Nutrition isn’t rocket science; it’s harder” A highly readable book that blows up common misconceptions, canards and profiteering charlatans, while wrestling with calories, #diets #precision nutrition #vitamins and more. Foundational for the public and the nutrition glitterati

Newly published treatment algorithm for the pharmacologic treatment of obesity and its complications, from the European Association for the Study of Obesity (EASO) ⚕️ Semaglutide and tirzepatide are recommended as first line to treat obesity AND to treat underlying

Multi-society consensus guidelines have stated there is no need to routinely hold GLP-1 prior to procedures. Here is another real-world analysis again showing the lack of any increased peri-procedure adverse events.

The new EASO framework shifts obesity care from BMI to health and lists #semaglutide and #tirzepatide as top treatments. Michael Weintraub, MD shares insights on what the framework could mean for care. 🎥 docwirenews.com/post/new-easo-… Beverly G. Tchang, MD Scott Isaacs Nature Portfolio

An overview of the design of the much awaited retatrutide triple agonist clinical trials

Diabetes is a progressive disease. Although we have several treatments with different mechanisms of action reduce average glucose levels, they all fail over time. The average time to treatment failure ranges from 2-2.5 years. We have yet to have a treatment that prevents the

Mark Cuban (Mark Cuban) testifies on Pharmacy Benefit Managers (PBMs) before the Senate Full video here: c-span.org/event/senate-c…

The US has the highest drug prices in the world. The US is the only country that has Pharmacy Benefit Managers (PBMs). This whole drug pricing system is corrupt and the losers are healthcare providers and patients and the winners are the insurance companies. We have to fix

Weight reduction was associated with reduced risk for depression, improved quality of life and functional status, regardless of the intervention (bariatric surgery, medication). There was no increase in adverse psychiatric events, suicidal ideation. There was no difference in

Within a year of discontinuing GLP-1s, more than half of patients with overweight/obesity or T2DM regained weight, with the greatest regain occurring in those who initially lost the most weight. NYU Langone Health Endocrinology Clinical Research shines at #OW2025

The clinical trial data for orforglipron has been reported. This is only the first step. We now await real-world data for post-marketing surveillance. Clinical trial populations do not equal real-world populations. Excellent talk by Dr. Donna Ryan at #ObesityWeek

Orforglipron leads as an oral small molecule GLP-1 receptor agonist for the treatment of type 2 diabetes and obesity. There’s a lot to follow.

Honored for the opportunity to present “Weight change after GLP-1 discontinuation in US patients living with overweight/obesity or diabetes” today during #ObesityWeek. Key takeaways: 📊 Only 38% remained adherent to GLP-1 medications after 12 months, in our real-world analysis

Eloralintide leads to a decrease in waist circumference. How much? “6.7 inches. Or about 6 to 7 inches.” 😂 Actual quote from #ObesityWeek.

🚨New eloralintide amylin agonist phase 2 results presented at #ObesityWeek 🚨 Highest doses generated weight reduction of ~20%. AE are GI events and fatigue, partially reduced with incorporating a dose escalation. 1mg arm has half the weight loss despite a fraction of the

Hypothalamic obesity is historically a challenging disease to treat. After brain surgery that may damage the hypothalamus with tumor resection there is a dramatic gain in weight. Two tools have recently gained impressive weight reduction data- GLP1 agonists and the MC4R agonist